A U.S. hemp stakeholder group has again criticized the government’s Food & Drug Administration (FDA) for drawing conclusions based on outdated research it says exaggerates the potential dangers of CBD.
In a letter sent yesterday to Senate and House committees, the U.S. Hemp Roundtable (USHR) blasted the agency for depending on studies based on highly concentrated pharmaceutical-grade CBD formulations, while ignoring more recent research since 2020 that shows low-dose over-the-counter extracts are safe.
Consumers would never be exposed to the amounts of CBD mentioned in the studies FDA references, USHR said, noting “Even essential nutrients like Vitamin D can be both beneficial and toxic depending on the dose.”
“As Congress develops plans to ensure the regulation of hemp extracts such as CBD, it should focus its attention on how these products are typically used, and not be distracted by studies that imagine their gross over-consumption which is not a realistic concern,” USHR General Counsel Jonathan Miller wrote in the letter, which was sent to the Senate Committee on Health, Education, Labor and Pensions, and the House Committee on Energy and Commerce.
“Combined with the low number of adverse events associated with CBD products and real-world, observational data that also points to the safety of CBD, the totality of the evidence paints a much different picture than what is presented by the FDA,” Miller wrote.
To read more, click on Hemp Today